TABLE 1.
Patients' characteristics
| Characteristics | N (%) | |
|---|---|---|
| Per‐protocol population | Lost to follow‐up population | |
| Total patients | 52 | 13 |
| Median age (range, y) | 55.5 (28‐73) | 55.0 (43‐69) |
| Age (median) | ||
| <60 | 33 (63.5) | 9 (69.2) |
| ≥60 | 19 (36.5) | 4 (30.8) |
| Histological type | ||
| High‐grade serous carcinoma | 48 (92.3) | 12 (92.3) |
| Clear cell carcinoma | 2 (3.8) | 0 |
| Endometrioid adenocarcinoma | 2 (3.8) | 1 (7.7) |
| FIGO stage for first‐line treatment | ||
| IC | 3 (5.8) | 0 |
| IIB | 7 (13.5) | 2 (15.4) |
| IIIA | 2 (3.8) | 1 (7.7) |
| IIIB | 1 (1.9) | 1 (7.7) |
| IIIC | 31 (59.6) | 9 (69.2) |
| IVB | 5 (9.6) | 0 |
| NA | 3 (5.8) | 0 |
| Prior lines of chemotherapy | ||
| <3 | 19 (36.5) | 1(7.7) |
| 3‐6 | 30 (57.7) | 10 (76.9) |
| >6 | 3 (5.8) | 2(15.4) |
| Regimen of last chemotherapy | ||
| Platinum‐based | 33 (63.5) | 10 (76.9) |
| Non‐platinum‐based | 19 (36.5) | 3 (23.1) |
| Platinum status | ||
| Refractory | 11 (21.2) | 1(7.7) |
| Resistant | 41 (78.8) | 12 (92.3) |
| Symptomatic | ||
| No | 16 (30.8) | 5 (38.5) |
| Yes | 36 (69.2) | 8 (61.5) |
| Measurable lesion | ||
| Yes | 11 (21.2) | 5 (38.5) |
| No | 41 (78.8) | 8 (61.5) |
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; NA, Non‐available.